



(11)

EP 2 494 037 B8

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
C12N 5/0781 ^(2010.01) **C07K 14/705** ^(2006.01)
C07K 16/00 ^(2006.01) **C07K 16/46** ^(2006.01)
C12N 15/62 ^(2006.01)

(48) Corrigendum issued on:
18.03.2015 Bulletin 2015/12

(86) International application number:
PCT/EP2010/006633

(45) Date of publication and mention
of the grant of the patent:
11.02.2015 Bulletin 2015/07

(87) International publication number:
WO 2011/050985 (05.05.2011 Gazette 2011/18)

(21) Application number: **10773585.4**

(22) Date of filing: **29.10.2010**

(54) **CLONAL EXPANSION OF B CELLS**

Klonale Expansion von B-Zellen

Expansion clonique de lymphocytes B

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

- **HOFF, Holger**
55122 Mainz (DE)
- **SCHUMACHER, Jens**
69120 Heidelberg (DE)

(30) Priority: **30.10.2009 EP 09013690**

(43) Date of publication of application:
05.09.2012 Bulletin 2012/36

(74) Representative: **Schnappauf, Georg et al**
ZSP Patentanwälte
Partnerschaftsgesellschaft
Radtkoferstrasse 2
81373 München (DE)

(73) Proprietors:

- **BioNTech AG**
55131 Mainz (DE)
- **Universitätsmedizin der**
Johannes Gutenberg-Universität Mainz
55131 Mainz (DE)

(56) References cited:
EP-A- 0 434 879

(72) Inventors:

- **SAHIN, Ugur**
55116 Mainz (DE)
- **TÜRECI, Özlem**
55116 Mainz (DE)
- **SEPPMANN, Torsten**
55116 Mainz (DE)

- **HANKS B A ET AL: "Re-engineered CD40**
receptor enables potent pharmacological
activation of dendritic-cell cancer vaccines in
vivo", NATURE MEDICINE, NATURE
PUBLISHING GROUP, NEW YORK, NY, US LNKD-
DOI:10.1038/NM1183, vol. 11, no. 2, 23 January
2005 (2005-01-23), pages 130-137, XP002399130,
ISSN: 1078-8956

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 494 037 B8

- LAPTEVA NATALIA ET AL: "Enhanced activation of human dendritic cells by inducible CD40 and toll-like receptor-4 Ligation", CANCER RESEARCH, vol. 67, no. 21, November 2007 (2007-11), pages 10528-10537, XP2540324, ISSN: 0008-5472

- BANCHEREAU J ET AL: "LONG-TERM HUMAN B CELL LINES DEPENDENT ON INTERLEUKIN-4 AND ANTIBODY TO CD40", SCIENCE (WASHINGTON D C), vol. 251, no. 4989, 1991, pages 70-72, XP002576462, ISSN: 0036-8075